The centre of excellence is funded by a grant from the Prostate Cancer Foundation (PCF) and comprises a multi-disciplinary team including nuclear medicine, medical oncology, radiation oncology, urology and laboratory-based doctors and researches with a strong patient-centred philosophy.
ProsTIC at Peter Mac is a world-leader in theranostics.
Meet the ProsTIC leadership team, scientific advisory team, CEO steering committee and staff.
This animation explains PSMA theranostics, a treatment that is increasingly being used for people with advanced prostate cancer and the focus of the world-leading research at ProsTIC at Peter Mac.
Clinical trials enable us to answer questions about what is the role of this new technology in improving patient care.
What do men do if they are deemed ineligible for the PSMA treatments available through ProsTIC?
Radiolabelled prostate specific membrane antigen (PSMA) can be used for PET imaging and also treatment of patients with prostate cancer.
ProsTIC's world leading research in the news.
Centres of Excellence do not evolve on their own. They require the best team, processes and purpose to realise a goal.